Precision HBV Care Moves Toward Functional Cure : Frontline Gastroenterology | May 2026

Introduction

Chronic Hepatitis B remains a leading global cause of cirrhosis and Hepatocellular Carcinoma despite the availability of potent antiviral therapy. However, management strategies are rapidly evolving from simple viral suppression toward precision, biomarker-driven care focused on long-term disease modification and functional cure.

Problem Statement

Traditional hepatitis B management has relied heavily on alanine aminotransferase levels and HBV DNA thresholds, which may fail to identify patients at ongoing risk of fibrosis progression and hepatocellular carcinoma, particularly those with concurrent metabolic dysfunction.

Summary

This contemporary review highlights the major clinical and conceptual advances incorporated into the 2025 European Association for the Study of the Liver hepatitis B guidance, outlining a shift toward earlier treatment, integrated metabolic assessment and personalized biomarker-led management.

A central theme is the movement toward achieving “functional cure,” defined by sustained loss of hepatitis B surface antigen with durable viral suppression. This represents a major evolution from the previous strategy of indefinite viral suppression alone.

The review emphasizes that patients with concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease may experience fibrosis progression even in the setting of low viral replication or normal liver enzymes. This recognition substantially broadens the clinical framework for treatment decision-making.

Novel viral biomarkers are increasingly reshaping hepatitis B management. Quantitative HBsAg, hepatitis B core-related antigen and HBV RNA are emerging as clinically important tools for refining disease phase classification, predicting treatment response and identifying patients suitable for safe therapy discontinuation.

These biomarkers may also help identify patients with lower intrahepatic viral transcriptional activity who are closer to achieving immune control.

Importantly, the review highlights that hepatitis B is no longer viewed solely as a virological disease but increasingly as a complex interaction between viral activity, host immunity, fibrosis biology and metabolic dysfunction.

The updated paradigm supports earlier antiviral initiation in selected patients before advanced fibrosis develops, reflecting growing evidence that cumulative inflammatory injury drives long-term hepatocarcinogenesis.

Special populations receive significant attention, including pregnant individuals, patients receiving immunosuppressive therapy and those with Hepatitis D co-infection, where tailored management strategies are essential.

The review also highlights emerging minimally invasive liver fine needle aspiration approaches that allow intrahepatic immune and virological profiling. These technologies may accelerate development of individualized immunotherapeutic and antiviral strategies.

Clinically, this transition mirrors broader trends in hepatology toward precision medicine, where treatment decisions increasingly integrate virological, metabolic, immunologic and fibrosis-related data rather than relying on isolated laboratory thresholds.

The article is particularly relevant because current nucleos(t)ide analogues rarely achieve HBsAg loss, creating strong interest in finite-treatment and immune-restorative strategies.

Several investigational therapeutic approaches are discussed indirectly within this evolving framework, including siRNA therapies, capsid assembly modulators, therapeutic vaccines and immune checkpoint-targeting approaches designed to restore antiviral immunity.

The review additionally underscores the importance of improving screening and linkage-to-care pathways, especially in migrant and underserved populations where hepatitis B burden remains concentrated.

Limitations remain substantial. Many emerging biomarkers are not yet globally standardized, treatment cessation strategies remain incompletely validated and access to advanced testing varies considerably across healthcare systems.

Future hepatitis B care will likely involve integrated risk prediction models combining viral biomarkers, metabolic phenotyping, fibrosis assessment and immune profiling to individualize treatment intensity and duration.

Overall, this review captures a major transition in chronic hepatitis B management—from static viral suppression algorithms toward biomarker-guided precision hepatology focused on earlier intervention, individualized monitoring and ultimately functional cure.